389 related articles for article (PubMed ID: 25151225)
1. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
[TBL] [Abstract][Full Text] [Related]
2. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
White AD; Sibley L; Dennis MJ; Gooch K; Betts G; Edwards N; Reyes-Sandoval A; Carroll MW; Williams A; Marsh PD; McShane H; Sharpe SA
Clin Vaccine Immunol; 2013 May; 20(5):663-72. PubMed ID: 23446219
[TBL] [Abstract][Full Text] [Related]
6. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
[TBL] [Abstract][Full Text] [Related]
8. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
Satti I; Marshall JL; Harris SA; Wittenberg R; Tanner R; Lopez Ramon R; Wilkie M; Ramos Lopez F; Riste M; Wright D; Peralta Alvarez MP; Williams N; Morrison H; Stylianou E; Folegatti P; Jenkin D; Vermaak S; Rask L; Cabrera Puig I; Powell Doherty R; Lawrie A; Moss P; Hinks T; Bettinson H; McShane H
Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38621405
[TBL] [Abstract][Full Text] [Related]
9. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Minhinnick A; Satti I; Harris S; Wilkie M; Sheehan S; Stockdale L; Manjaly Thomas ZR; Lopez-Ramon R; Poulton I; Lawrie A; Vermaak S; Le Vert A; Del Campo J; Hill F; Moss P; McShane H
Vaccine; 2016 Mar; 34(11):1412-21. PubMed ID: 26854906
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
[TBL] [Abstract][Full Text] [Related]
11. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
Meyer J; Harris SA; Satti I; Poulton ID; Poyntz HC; Tanner R; Rowland R; Griffiths KL; Fletcher HA; McShane H
Vaccine; 2013 Feb; 31(7):1026-33. PubMed ID: 23266342
[TBL] [Abstract][Full Text] [Related]
12. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Wajja A; Kizito D; Nassanga B; Nalwoga A; Kabagenyi J; Kimuda S; Galiwango R; Mutonyi G; Vermaak S; Satti I; Verweij J; Tukahebwa E; Cose S; Levin J; Kaleebu P; Elliott AM; McShane H
PLoS Negl Trop Dis; 2017 May; 11(5):e0005440. PubMed ID: 28472067
[TBL] [Abstract][Full Text] [Related]
13. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Pathan AA; Minassian AM; Sander CR; Rowland R; Porter DW; Poulton ID; Hill AV; Fletcher HA; McShane H
Vaccine; 2012 Aug; 30(38):5616-24. PubMed ID: 22789508
[TBL] [Abstract][Full Text] [Related]
14. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
von Reyn CF; Lahey T; Arbeit RD; Landry B; Kailani L; Adams LV; Haynes BC; Mackenzie T; Wieland-Alter W; Connor RI; Tvaroha S; Hokey DA; Ginsberg AM; Waddell R
PLoS One; 2017; 12(5):e0175215. PubMed ID: 28498853
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
18. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans.
Jeyanathan M; Fritz DK; Afkhami S; Aguirre E; Howie KJ; Zganiacz A; Dvorkin-Gheva A; Thompson MR; Silver RF; Cusack RP; Lichty BD; O'Byrne PM; Kolb M; Medina MFC; Dolovich MB; Satia I; Gauvreau GM; Xing Z; Smaill F
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34990408
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
Tameris M; Hokey DA; Nduba V; Sacarlal J; Laher F; Kiringa G; Gondo K; Lazarus EM; Gray GE; Nachman S; Mahomed H; Downing K; Abel B; Scriba TJ; McClain JB; Pau MG; Hendriks J; Dheenadhayalan V; Ishmukhamedov S; Luabeya AK; Geldenhuys H; Shepherd B; Blatner G; Cardenas V; Walker R; Hanekom WA; Sadoff J; Douoguih M; Barker L; Hatherill M
Vaccine; 2015 Jun; 33(25):2944-54. PubMed ID: 25936724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
